Kilitch Drugs (India) Limited (KILITCH) AI Stock Analysis

• Market Cap: ₹6.56B
• Dividend Yield: N/A
• Average Volume (3M): 2.19K
• Price to Earnings (P/E): 22.0
• Beta (1Y): 0.99
• Revenue Growth: 37.51%
• EPS Growth: 122.52%
• Country: IN
• Employees: 168
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.84
• Shares Outstanding: 17,480,782
• 10 Day Avg. Volume: 2,304
• 30 Day Avg. Volume: 2,185
• PEG Ratio: 0.27
• Price to Book (P/B): 2.86
• Price to Sales (P/S): 2.92
• P/FCF Ratio: -19.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: ₹397.00 ▲(6.26% Upside)

Kilitch Drugs' strong financial performance, particularly in revenue growth and profit margins, is a key strength. However, technical indicators suggest potential bearish momentum, and cash flow management needs improvement. The stock's valuation is reasonable, but the lack of a dividend yield may deter income investors.

Kilitch Drugs (India) Limited Business Overview & Revenue Model

Company Description

Kilitch Drugs (India) Limited (KILITCH) is a prominent pharmaceutical company based in India, specializing in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company operates in various sectors, including generic and branded formulations, and focuses on therapeutic areas such as anti-infectives, anti-inflammatory drugs, and cardiovascular medications. Kilitch is committed to quality and compliance, ensuring that its products meet stringent regulatory standards, which allows it to serve both domestic and international markets effectively.

How the Company Makes Money

Kilitch Drugs generates revenue primarily through the sale of its pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company has diversified its revenue streams by engaging in contract manufacturing for other pharmaceutical firms, which allows it to leverage its production capabilities. Additionally, Kilitch explores international markets, exporting its products to various countries, which contributes significantly to its earnings. Strategic partnerships with healthcare providers and other pharmaceutical companies enhance its market presence and drive sales. The company's focus on research and development also enables it to innovate and introduce new products, further bolstering its revenue potential.

Kilitch Drugs (India) Limited Financial Statement Overview

Summary

Kilitch Drugs shows strong revenue growth and improved profit margins, indicating robust financial health. However, operational efficiency and cash flow management need improvement, as evidenced by the moderate EBIT and EBITDA margins and challenges in converting earnings into cash flow.

Income Statement

Kilitch Drugs has demonstrated robust revenue growth with a notable increase in total revenue from previous years. The gross profit margin is healthy, indicating effective cost management. Net profit margin has improved significantly, showcasing enhanced profitability. However, the EBIT and EBITDA margins, although positive, suggest room for improvement in operational efficiency.

Balance Sheet

The company's balance sheet reflects a strong equity position with a favorable equity ratio. The debt-to-equity ratio is moderate, suggesting a balanced approach to leverage. Return on Equity (ROE) indicates a positive return on shareholder investments, although it could be further optimized. Overall, the balance sheet is stable but has potential for better utilization of assets.

Cash Flow

The cash flow statement shows challenges in free cash flow, with negative growth in recent periods due to increased capital expenditures. The operating cash flow to net income ratio is positive but indicates that the company is facing difficulties in translating earnings into cash flow. Improvements in cash management could enhance financial flexibility.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.08B	1.98B	1.54B	1.40B	1.14B	681.28M
Gross Profit	1.00B	937.39M	731.38M	624.64M	337.44M	300.07M
EBITDA	442.15M	426.26M	287.43M	206.50M	134.13M	79.85M
Net Income	280.03M	267.01M	146.01M	104.48M	73.67M	36.71M
Balance Sheet
Total Assets	0.00	3.13B	2.40B	2.20B	2.10B	2.03B
Cash, Cash Equivalents and Short-Term Investments	593.65M	593.98M	690.19M	591.77M	572.43M	488.49M
Total Debt	0.00	494.24M	316.46M	221.94M	204.32M	148.04M
Total Liabilities	-2.00B	1.12B	643.88M	689.41M	695.55M	736.97M
Stockholders Equity	2.00B	2.02B	1.76B	1.52B	1.39B	1.27B
Cash Flow
Free Cash Flow	0.00	-293.31M	-65.97M	-12.26M	-24.19M	93.61M
Operating Cash Flow	0.00	175.42M	-1.46M	25.86M	57.83M	456.59M
Investing Cash Flow	0.00	-399.47M	-95.45M	79.15M	-152.50M	-375.69M
Financing Cash Flow	0.00	132.43M	88.07M	-7.16M	70.28M	16.14M

Kilitch Drugs (India) Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 373.60
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KILITCH, the sentiment is Positive. The current price of 373.6 is above the 20-day moving average (MA) of 358.02, above the 50-day MA of 371.43, and below the 200-day MA of 374.96, indicating a neutral trend. The MACD of 1.17 indicates Negative momentum. The RSI at 56.76 is Neutral, neither overbought nor oversold. The STOCH value of 32.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:KILITCH.

Kilitch Drugs (India) Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	69 Neutral	₹6.06B	11.28	―	―	9.15%	88.32%
INDSWFTLAB	66 Neutral	₹7.45B	2.95	―	―	-68.96%	-30.30%
KILITCH	64 Neutral	₹6.56B	22.02	―	―	37.51%	122.52%
SAKAR	64 Neutral	₹7.72B	39.03	―	―	21.65%	73.16%
MEDICAMEQ	59 Neutral	₹4.41B	49.73	―	0.27%	-9.90%	33.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NECLIFE	43 Neutral	₹3.11B	30.02	―	―	-3.41%	-3028.44%

Kilitch Drugs (India) Limited Corporate Events

Kilitch Drugs Announces Details for 33rd AGM

Kilitch Drugs (India) Limited has announced the details of its 33rd Annual General Meeting (AGM) through a newspaper publication. The AGM will address key corporate matters such as book closure, e-voting, and the availability of the Annual Report for the financial year 2024-25 on the company’s website and stock exchanges. This announcement is part of the company’s compliance with SEBI regulations, ensuring transparency and accessibility for its stakeholders.

Kilitch Drugs Announces 33rd AGM with Key Leadership Reappointments

Kilitch Drugs (India) Limited has announced its 33rd Annual General Meeting (AGM) scheduled for September 26, 2025, to be conducted via video conferencing. The AGM will address ordinary business such as the adoption of financial statements and the reappointment of directors, including Mr. Bhavin Mehta and Mr. Mukund Mehta, the latter as Managing Director for another five years. This meeting is significant for stakeholders as it involves key decisions on leadership and financial strategies that could impact the company’s future operations and market positioning.

Kilitch Drugs Announces AGM Amidst Market Adjustments

Kilitch Drugs (India) Limited has announced a public notice regarding its 8th Annual General Meeting and e-voting information. This announcement is part of a broader context of financial and regulatory updates affecting the market, including rising government bond yields due to fiscal concerns and regulatory changes in India’s derivatives market. The bond market is experiencing pressure due to fiscal slippage worries and a lack of buyers, while the Securities and Exchange Board of India’s plans to extend derivative contract tenures could impact market liquidity. These developments reflect ongoing adjustments in the financial sector, which stakeholders should monitor closely.

Kilitch Drugs Approves Rights Issue to Strengthen Capital

Kilitch Drugs (India) Limited announced the approval and allotment of 13,98,463 equity shares on a rights basis to eligible shareholders at an issue price of Rs. 357 per share. This move, approved by the Board of Directors, is expected to enhance the company’s capital structure and provide additional resources for its operational and strategic initiatives.

Kilitch Drugs Postpones Rights Issue Share Credit and Listing Dates

Kilitch Drugs (India) Limited announced a postponement in the credit and listing dates for its Rights Issue shares, initially scheduled for August 25 and 26, 2025, now moved to August 26 and 28, 2025. This delay, related to the finalization of the basis of allotment, may impact shareholders and market expectations, as the company had previously communicated the Rights Issue details and schedule.